本帖最后由 老马 于 2012-1-13 21:20 编辑 $ [, k7 T3 u1 } z
% i2 N( M# n2 q% q Y/ O爱必妥和阿瓦斯丁的比较9 D9 b7 u7 w8 r9 H
) E5 Z) _0 T' Q* B E2 v1 R6 l
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 E4 U w; }2 X8 u" S
4 q3 {! e6 U* m4 H, J
3 U( y+ {- S, B( i# J" G9 a e
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 B1 u9 @1 j3 g0 [$ {* n( b==================================================# s; [7 L p' C1 e7 d* T
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ j5 v9 n7 X$ T/ j/ ~" p" D" g% X
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 P' i+ f( D( f' f7 M. k! A( rResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 C7 E7 m3 ]+ @
|